01/26-27/16 Flashcards
Congestive Heart Failure: Background
- slow/progressive decline in cardiac output
- heart unable to perfuse organs
- acute decompensated heart failure
- immediate treatment
- ~5 million with CHF in USA
- chronic disease: years to develop
Compensatory mechanisms in CHF
- Increase SNS output
- Increase RAAS activity
- Increase plasma volume
- Increase heart rate
- Increase blood pressure
- Increase cardiovascular remodeling

Frank-Starling curve in CHF patients

Spiral into CHF
- Example of body making the situation worse
- Release transmitters to increase BP, enothelin, angiotensin II
- Increase afterload because constricts blood vessels. Makes heart have to work harder
- Decreased ejection fraction. Less blood out of heart because hard to push blood out
- Lots of other bad things happen from chronic NE and AT II release

Symptoms of CHF
- shortness of breath
- coughing/wheezing
- edema
- fatigue
- lack of appetite, nausea
- confusion
- tachycardia/arrhythmia
CHF patient classification
- Class I
- no symptoms
- Class II
- mild symptoms
- comfortable at rest
- Class III
- marked limitation in activity
- only comfortable at rest
- Class IV
- severe activity limitations
Stages of Heart Failure and recommended intervention

Cardiac Glycosides
- Digitoxin (Crystodigin)
- Digoxin (Lanoxin)
- isolated from digitalis species of herbaceous perennials
Cardiac Glycosides: MOA
- inhibit Na+/K+ ATPase
- Increase [Na+]i
- Decrease Ca2+/Na+ exchange
- Increase [Ca2+]i
- Increase Ca2+ uptake into ER/SR by SERCA2 transporter
- NCX activity depands upon Na+/K+ ATPase; because can’t go out of the NCX, more calcium intracellular. At the next heart beat, there is more calcium, makes a stronger contraction.
- Increase inotropy (force of contraction)
- Increase stroke volume
- Increase PSNS activity
- Decrease HR
Cardiac Glycosides: Electrical Effects
- Increase intracellular Na+ and Ca2+
- Increase resting membrane potential
- oscillatory depolarizing afterpotentials

Cardiac Glycosides: Arrhythmias
- Afterpotentials elicit action potentials in Purkinje fibers
- bigeminy: one abnormal beat per cardiac cycle
- Self-sustaining tachycardia
- ventricular fibrillation

Cardiac Glycosides: Pharmacokinetics
- 1 week for steady state levels to be reached
- serum levels: TI=2
- <0.9 ng/mL=safe
- >2 ng/mL=toxic
- use Digoxin antibody (Digibind) to find levels
- duration 36-40 h
- numerous DDI
- excreted unmetabolized in urine, unless…
- Eubacterium lentum: 10% of population
Symptoms of Cardiac Glycoside toxicity
- CNS:
- delirium, malaise, dizziness, abnormal dreams
- Visual:
- blurred vision, yellow halos
- Cardiac:
- atrial and ventricular arrhythmias, SA/AV node block
- GI:
- anorexia, nausea, vomiting, abdominal pain
- Respiratory:
- enhanced ventilatory response to hypoxia
Cardiac Glycoside: Clinical Use
- Only oral ionotropic agent recommended for CHF
- Increase quality of life/exercise tolerance
- does not treat underlying disease progression
- recommended for CHF with AFib
- DIG trial:
- 1997, ~6800 patients with Stage II-III CHF
- ACE inhibitor + placebo or digoxin
- Decrease risk of CHF mortality
- Increase risk of arrhythmia mortality
- net effect: no difference in mortalitly rates!
Beta-adrenergic receptor antagonists
- Cardioselective (Beta1-ARs)
- Metoprolol (Lopressor)
- Bisoprolol (Zebeta)
- Mixed selectivity (alpha1/beta1-ARs)
- Carvedilol (Coreg)
Beta-adrenergic receptor antagonists: MOA
- Antagonise cardiac beta1-ARs
- decrease HR, decrease CO
- decrease arrhythmias
- decrease cardiac remodeling
- Angatonize renal beta1-ARs
- decrease renin release, decrease AT II/aldosteronse
- decrease afterload, TPR
- Carvedilol: antagonize vascular alpha1-ARs
- decrease afterload, TPR
Beta-adrenergic receptor antagonists: Clinical Use in CHF
- recommended for CHF II-III
- use with ACE-inhibitor, diuretic
- increase lifespan (probably because decrease odds of arrhythmia)
Beta-adrenergic receptor antagonists: toxicity
- bradycardia
- nausea
ACE-Inhibitors
- Captopril (Capoten)
- Enalapril (Vasotec)
- Ramipril (Altace)
ACE-Inhibitors: MOA
- Inhibit ACE
- Decrease ATII production
- Decrease aldosterone/VP→decrease plasma volume
- Decrease afterload/total peripheral resistance
- Decrease CVS remodeling
ACE-Inhibitors: Clinical Use in CHF
- 1st line therapy for CHF
- Decrease CHF mortalilty and morbidity
- use with diuretics
ACE-Inhibitors: Toxicity
- severe hypotension
- cough reflex
- angioedema
- hyperkalemia
- teratogenic
Angiotensin II receptor antagonists
- Losartan (Cozaar)
- Olmesartan (Benicar)
- Telmisartan (Micardis)
Angiotensin II receptor antagonists: MOA
- inhibit ATII type 1 receptor
- type 2 work on endothelium; stimulating type 2, NO production and vasodilation; type 1 effects will win over type 2. These drugs are selective to type 1. AT-II still floating around body, but now can work on the type 2 receptors
- No effect on ATII production
- Decrease aldosterone/VP→decrease plasma volume
- Decrease afterload/total peripheral resistance
- Decrease CVS remodeling
Angiotensin II receptor antagonists: Clnical Use in CHF
- 1st line therapy for CHF
- less data available than ACE-I on CHF morbidity and mortality
- use with diuretics
Angiotensin II receptor antagonists: toxicity
- severe hypotension
- NO cough reflex
- less angioedema
- hyperkalemia
- tertogenic
Thiazides
- hydrochlorothiazide (Microzide)
Thiazides: MOA
- inhibit apical Na+/Cl- transporter (NCC) in DCT
Thiazides: Toxicity
- hypokalemic metabolic alkalosis
Thiazides: Use in CHF
- Initial therapy for CHF
- Decrease SBP ~10-15 mmHg
- Decrease afterload and preload
- Ineffective with GFR <30 mL/min
- Monitor serum electrolytes to prevent hypokalemia
- Combine with K+ sparing diuretics, supplements
- Diuretic resistance
- Hypomagnesemia/hyperuricemia with long term use
Loop Diuretics
- Furosemide (Lasix)
Loop Diuretics: MOA
- inhibit apical Na+/K+/2Cl- transporter (NKCC2) in TALOH
Loop Diuretics: Toxicity
- hypokalemic metabolic alkalosis
Loop Diuretics: Use in CHF
- Oral for CHF
- monitor serum electrolytes to prevent hypokalemia
- IV for acute decompensated heart failure
- Decrease peripheral/pulmonary edema
- Increase dosage with renal impairment
- Diuretic resistance
K+ sparing diuretics: aldosterone antagonists
- Eplerenone (Inspra)
- Spironolactone (Aldactone)
- Decrease efficacy compared to loop/thiazide
- use with loop/thiazide diuretics to offset hypokalemia/hypomagnesemia
K+ sparing diuretics: aldosterone antagonists
RALES trial
- Additive effects with ACE inhibitors
- Increase survival in CHF patients independent of diuresis
K+ sparing diuretics: aldosterone antagonists
Toxicity
- Hyperkalemia
- gynecomastia (with spironolactone but not eplerenone)
- ototoxicity (reversible)
- metabolic alkalosis
Neprilysin Inhibitors
- Sacubitril and Valsartan combination therapy (Entresto)
Entresto: MOA
- Valsartan: ATII-1 receptor antagonist
- Sacubitril: neprilysin inhibitor
- enzyme that breaks down atrial/brain natriuritic factor
- vasodilation
- decreases preload/afterload
- Decrease TPR
Entresto: Clincal use in CHF
- PARDIGM-HF study
- superior to ACE-inhibitors to reduce risk of death in chronic heart failure patients with reduced ejection fraction
Entresto: toxicity
- angioedema
- hypotension
- long term effects?
Diagram of factors contributing to CHF

Acute Decompensated Heart Failure
- most common indication for emergency care
- >1 million admissions annually in USA
- Common causes:
- CHF, pneumonia, MI, arrhythmia, hypertension
- Goals:
- Increase CO
- Increase oxygen delivery
Phosphodiesterase-3 Inhibitors
- Amrinone (Inocor)
- Milrinone (Primacore)
- Enoximone (Perfan)
Phosphodiesterase-3 Inhibitors: MOA
- Inhibit PDE III→increases cAMP→increases PKA activity
- Cardiac: increase L-type Ca2+ channel opening→increase CO
- Vascular: increases K+ channel opening→vasodilation
Phosphodiesterase-3 Inhibitors: Clinical use in CHF
- IV for acute decompensated heart failure
- Increase HF morbidity and mortality
- short duration of action (minutes)
Phosphodiesterase-3 Inhibitors: toxicity
- arrhythmia
Sympathomimetics
- Positive inotropic agents used during ADHF that mimic SNS
- NE/EPI: rarely used
-
Dopamine:
- <2ug/kg: stimulate VSMC D1/D2 autoreceptors
- vasodilation
- 2-5 ug/kg: stimulate cardiac beta1-ARs
- increase cardiac output
- 5-15 ug/kg: stimulate VSMC alpha1-ARs
- vasoconstriction
- <2ug/kg: stimulate VSMC D1/D2 autoreceptors
-
Dobutamine
-
stimulate cardiac beta1-ARs
- increase cardiac output
-
stimulate cardiac beta1-ARs
Vasodilators
- Nesiritide (Natrecor)
- Nitroprusside (Nitropress)
- Isosorbide dinitrate/Hydralizine (BiDil)
Vasodilators: MOA
- Increase NO in vascular smooth muscle
- Vasodilation
- Decrease preload/afterload
- Decrease TPR
Vasodilators: Clinical Uses in CHF
- IV: Nesiritide or Nitroprusside for acute decompensated heart failure
- Oral: isosorbide dinitrate/hydralazine for CHF patients unresponsive to diuretics/ACE-I/ARB
Vasodilators: Toxicity
- Reflex tachycardia
- Hypotension
- Headache/dizziness
Digoxin: Drug Card
- Brand Name:
- Lanoxin
- MOA:
- Inhibit Na+/K+ ATPase
- Clincal Uses:
- CHF
- arrhythmias
- Toxicity:
- Arrhythmogenic
- Nausea, malaise, diarrhea
- Vision problems
- Extra Info:
- Only approved cardiotonic agent for CHF
- No net effect on CHF mortality
- Low therapeutic index (~2)
Metoprolol: Drug Card
- Brand Name:
- Lopressor
- MOA:
- selective beta-1 adrenergic receptor antagonist
- Clinical Uses:
- CHF
- HTN
- Toxicities:
- Bradycardia, atroventricular block
- CNS sedation
- Extra Info:
- Shown to reduce mortality in heart failure patients
- widely used for Stage I/II hypertension
Carvedilol: Drug Card
- Brand Name:
- Coreg
- MOA:
- mixed alpha-1 and beta-adrenergic receptor antagonist
- Clinical Uses:
- CHF
- HTN
- Toxicities:
- Bradycardia, atrioventricular block
- CNS sedation
- less bronchospasm
- Extra Info:
- Composed of 4 stereoisomers
- Shown to reduce mortality in heart failure patients
Captopril: Drug Card
- Brand Name:
- Capoten
- MOA:
- Inhibit angiotensin-converting enzyme (ACE)
- Clinical uses:
- Stage I/II hypertension
- CHF
- diabetic renal disease
- Toxicities
- bradykinin cough reflex
- hyperkalemia
- teratogenic
- Extra Info:
- oral
- effective up to 12 hours
Losartan: Drug Card
- Brand Name:
- Cozaar
- MOA:
- Angiotensin-II type I receptor antagonist
- Clinical Uses:
- Stage I/II hypertension
- CHF
- Toxicities:
- Hyperkalemia
- Teratogenic
- Extra Info:
- Oral
- No cough reflex
Furosemide: Drug Card
- Brand Name:
- Lasix
- MOA:
- inhibit Na+/K+/2Cl- cotransporter (NKCC2) in thick ascending limb of Henle
- Clincal Uses:
- edema in CHF, cirrhosis, nephrotic syndrome
- hypertension
- hypercalcemia
- Toxicities:
- hypokalemia
- ototoxicity
- dehydration
- Extra info:
- “high ceiling diuretic”
- rapid onset of action (minutes)
Hydrochlorothiazide: Drug Card
- Brand Name:
- Microzide
- MOA:
- Inhibit Na+/Cl- co-transporter (NCC) in distal convoluted tubule
- Clinical Uses:
- HTN
- CHF
- idiopathic hypercalciuria
- Toxicities:
- hypokalemic metabolic alkalosis
- hyponatremia
- hyper-lipidemia, uricemia, calcemia
- Extra info:
- “low ceiling diuretic”
- component of many combination therapies
Spironolactone: Drug Card
- Brand Name:
- Aldactone
- MOA:
- competitive antagonist of aldosterone receptor
- Clincal Uses:
- hyperaldosteronism
- CHF
- HTN
- Toxcities:
- hyperkalemia
- endrocrine effects (i.e. gynecomastia)
- Extra info:
- used in combination with loop or thiazides to prevent hypokalemia
- eplerenone lacks anti-androgen effects
Amrinone: Drug Card
- Brand Name:
- Inocor
- MOA:
- Phosphodiesterase-3 inhibitor
- Clinical uses:
- acute decompensated heart failure
- Toxicities:
- arrhythmia
- Extra Info:
- IV for acute decompensated heart failure
- short duration (minutes)
Dobutamine: Drug Card
- Brand Name:
- Dobutamine
- MOA:
- beta-1 adrenergic receptor agonist
- Clinical uses:
- Acute decompensated heart failure
- Toxicities:
- arrhythmia
- Extra info:
- IV for acute decompensated heart failure
- short duration (minutes)
Nitroprusside: Drug Card
- Brand Name:
- Nitropress
- MOA:
- nitrovasodilator; nitric oxide donor
- Clinical Uses:
- acute decompensated heart failure
- Toxicities:
- tachycardia
- excessive hypotension
- Extra Info:
- IV for acute decompensated heart failure
- short duration (min)
Hydralazine+Isosorbide Dinitrate: Drug card
- Brand Name:
- Bidil
- MOA:
- Hydralazine: vascular K+ channel opener
- ID: nitric oxide donor, nitrovasodilator
- Clinical Uses:
- CHF
- angina
- Toxicities
- reflex tachycardia
- excessive hypotension
- headache
- Extra Info:
- oral, long duration of action